TrialNature cancer2026

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

Solange Peters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.